Tags

Type your tag names separated by a space and hit enter

Diagnosis and treatment of premenstrual dysphoric disorder: an update.
Int Clin Psychopharmacol. 2000 Nov; 15 Suppl 3:S5-17.IC

Abstract

Premenstrual dysphoric disorder (PMDD) appears in the appendix of the DSM-IV under the heading 'depressive disorder not otherwise specified'. Yet, recently, a group of experts reached a consensus that PMDD is a distinct clinical entity with characteristic symptoms of irritability, anger, internal tension, dysphoria, and mood lability. PMDD is the more severe form of premenstrual symptomatology, whereas premenstrual syndrome (PMS) is milder and more prevalent and both must be differentiated from premenstrual magnification/exacerbation of an underlying major psychiatric disorder or a medical condition. Accurate assessment and diagnosis of significant premenstrual symptomatology is paramount and can be influenced by subjective perception, retrospective versus prospective reporting, and cultural context. The serotonergic system, which is in a close reciprocal relationship with the gonadal hormones, has been identified as the most plausible target for intervention. Results from randomized placebo-controlled trials in women with PMDD have clearly demonstrated that serotonin reuptake inhibitors (SSRIs), with daily or intermittent dosing, have excellent efficacy and minimal adverse effects and should be considered first-line treatment. Luteal phase only SSRI administration may offer an attractive treatment option for a disorder that is itself intermittent. Hormonal interventions, in particular the suppression of ovulation will eliminate premenstrual symptomatology; however, the benefits-risk ratio of these approaches should be carefully evaluated with the patient.

Authors+Show Affiliations

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Women's Health Concerns Clinic and Father Sean O'Sullivan Research Centre, Hamilton, Ontario, Canada. mst@fhs.csu.mcmaster.caNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11195269

Citation

Steiner, M, and L Born. "Diagnosis and Treatment of Premenstrual Dysphoric Disorder: an Update." International Clinical Psychopharmacology, vol. 15 Suppl 3, 2000, pp. S5-17.
Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol. 2000;15 Suppl 3:S5-17.
Steiner, M., & Born, L. (2000). Diagnosis and treatment of premenstrual dysphoric disorder: an update. International Clinical Psychopharmacology, 15 Suppl 3, S5-17.
Steiner M, Born L. Diagnosis and Treatment of Premenstrual Dysphoric Disorder: an Update. Int Clin Psychopharmacol. 2000;15 Suppl 3:S5-17. PubMed PMID: 11195269.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnosis and treatment of premenstrual dysphoric disorder: an update. AU - Steiner,M, AU - Born,L, PY - 2001/2/24/pubmed PY - 2001/3/17/medline PY - 2001/2/24/entrez SP - S5 EP - 17 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 15 Suppl 3 N2 - Premenstrual dysphoric disorder (PMDD) appears in the appendix of the DSM-IV under the heading 'depressive disorder not otherwise specified'. Yet, recently, a group of experts reached a consensus that PMDD is a distinct clinical entity with characteristic symptoms of irritability, anger, internal tension, dysphoria, and mood lability. PMDD is the more severe form of premenstrual symptomatology, whereas premenstrual syndrome (PMS) is milder and more prevalent and both must be differentiated from premenstrual magnification/exacerbation of an underlying major psychiatric disorder or a medical condition. Accurate assessment and diagnosis of significant premenstrual symptomatology is paramount and can be influenced by subjective perception, retrospective versus prospective reporting, and cultural context. The serotonergic system, which is in a close reciprocal relationship with the gonadal hormones, has been identified as the most plausible target for intervention. Results from randomized placebo-controlled trials in women with PMDD have clearly demonstrated that serotonin reuptake inhibitors (SSRIs), with daily or intermittent dosing, have excellent efficacy and minimal adverse effects and should be considered first-line treatment. Luteal phase only SSRI administration may offer an attractive treatment option for a disorder that is itself intermittent. Hormonal interventions, in particular the suppression of ovulation will eliminate premenstrual symptomatology; however, the benefits-risk ratio of these approaches should be carefully evaluated with the patient. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/11195269/Diagnosis_and_treatment_of_premenstrual_dysphoric_disorder:_an_update_ L2 - https://medlineplus.gov/premenstrualsyndrome.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.